Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"text","content":"Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor HarmNationally Recognized Firm Urges Quantum Investors to Explore Class Action Representation\nNEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), and their broker-dealer subsidiaries (together, the “Defendants”). The action alleges that Defendants defrauded investors by placing and executing manipulative trades designed to artificially deflate the price of Quantum Biopharma Ltd. (“Quantum”) (NASDAQ: QNTM) securities. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that sold Quantum securities between January 6, 2021 and October 15, 2025, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/QNTM. Quantum Case Details The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: Defendants repeatedly entered thousands of spoofed sell orders designed to create the false appearance that Quantum’s stock price was declining; These manipulative orders were calculated to—and did—deceive or induce investors to sell their shares at artificially depressed prices; After driving the market price down, Defendants purchased Quantum shares at these artificially deflated levels, positioning themselves to profit from the scheme; and As a result of Defendants’ misconduct, investors, including Plaintiff, were improperly induced into selling their shares at artificially depressed prices. What's Next for Quantum Investors? A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/QNTM. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Quantum you h...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B